Pfizer announced that its combination therapy of BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib) has demonstrated ...
We welcome two special guests, Dr. Stacy Lindborg, and Dr. Premal Thaker, to discuss the results of the OVATION 2 Study and ...
The latest data from the Phase III NATALEE trial, presented at ESMO 2024, demonstrate that adding Kisqali (ribociclib) to standard endocrine therapy reduces the risk of breast cancer recurrence by ...
The European Commission has approved BRAFTOVI® and MEKTOVI® for treating advanced non-small cell lung cancer with the BRAFV600E mutation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback